media – Page 30 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

The World’s First Targeted Innovative Drug for Hepatitis B Approved for Market

On October 30, Xi’an Xintong Pharmaceutical Research Co., Ltd. held a press conference in the Silk Road Innovation and Smart Valley of Xi’an High-tech Zone to announce the approval of “Xinshi Mu,” a first-class innovative drug targeting hepatitis B. It is the commercial name approved for the drug Preadfovir mesylate tablets, which is indicated for the treatment of chronic hepatitis B in adults. The drug utilizes the HepDirect liver-targeted delivery system to concentrate the active ingredients in the target organ, enhancing efficacy and reducing toxicity. This makes it the world’s first approved liver-targeted innovative drug for hepatitis B. Zhang Denge, chairman of Xintong Pharmaceutical, stated that “Xinshi Mu” is part of the national major new drug creation projects during the 12th and 13th Five-Year Plans, with research beginning in 2011, and it took 13 years to gain approval for market release. Wang Liping, the Drug Safety Director of the Shaanxi ...
- Source: drugdu
- 71
- November 6, 2024
$1.4 billion deal highlights the future of Alzheimer’s disease therapy

The development of therapies for Alzheimer’s disease has always caused many developers to feel exhausted, and now AbbVie has also increased its investment in neurodegenerative diseases. AbbVie has agreed to spend $1.4 billion to acquire Aliada Therapeutics, whose main acquisition asset is Aliada’s authorized Alzheimer’s disease candidate drug ALIA-1758 from Johnson&Johnson. Its mechanism of action is still an anti beta amyloid protein (3pE-A β) antibody, but the unique feature of ALIA-1758 is that it can cross the blood-brain barrier, greatly improving the brain’s absorption rate. Aliada started a phase 1 trial among healthy volunteers in May, but AbbVie believes the timing is ripe for acquisition. Previously, AbbVie made the decision to abandon its internal Alzheimer’s disease asset ABBV-916. This anti beta amyloid antibody has no significant difference in safety and efficacy compared to the already marketed monoclonal antibody therapy for Alzheimer’s disease. Therefore, AbbVie decided to terminate the development ...
- Source: drugdu
- 70
- November 5, 2024
Interphex

Organiser：Pharmaceutical Research and Manufacturers of America (PhRMA) Time： April 1st – 3rd, 2025 Address：655 West 34th Street, New York, NY 10001-1188, USA Exhibition hall：Javits Convention Center, NYC Product range: Active Pharmaceutical Ingredients (APIs): Vitamins, hormones, cephalosporins, macrolides, central nervous system drugs, and other western medicine raw materials Excipients & Dosage Forms: Excipients, fluids, enteric coatings, antioxidants, sweeteners, osmotic agents, preservatives, disintegrants, clarifiers, pH adjusters, etc. Natural Extracts: Plant extracts, animal extracts, dietary fibers, cosmetic ingredients About Interphex： Interphex, the Biopharmaceutical Manufacturing & Technology Exhibition in New York, USA, is a leading event in the pharmaceutical and biotechnology industries, merging industry innovations with expert-led conferences. Since its inception in 1979, it has been the most trusted life science exhibition across both chemical and biopharmaceutical sectors in North America. Exhibitors have the opportunity to meet with decision-makers from top pharmaceutical companies worldwide through this exhibition.
- Source: drugdu
- 97
- November 5, 2024
Johnson&Johnson announces latest personnel changes

Recently, Larry Jones, Global Vice President and Group Chief Information Officer of Medical Technology at Johnson&Johnson (NYSE: JNJ), will leave the world’s second-largest medical device manufacturer. He will retire from Johnson&Johnson’s medical device business. The details of when and when the official resignation will take place, or who will take over, are still unknown. 01. Retirement of Group Chief Information Officer Recently, Larry Jones announced that he will retire from Johnson&Johnson’s medical device business. When asked when he will officially resign or if someone will replace him, he said he will share more details when the information becomes public. Johnson&Johnson Medical Technology did not respond to further information requests. Jones is a goal oriented leader who achieves transformational change through key principles such as business process integration, agile methods, and next-generation technology solutions. He focuses on driving digital surgical connectivity solutions for Johnson&Johnson’s oncology, orthopedics, cardiovascular, and general surgery robots ...
- Source: drugdu
- 60
- November 5, 2024
Sonavex announces completion of new round of financing

According to the Medicine Intelligence Data Investment Pattern Database, Sonavex, an innovative ultrasound technology company, recently announced the completion of a $15 million (contract RMB 106 million) Series A-2 financing to support its ultrasound technology. This round of financing has attracted several new investors and received strong participation from existing shareholders and industry veterans. Sonavex is a medical device company located in Baltimore, Maryland, spun off from Johns Hopkins University. Sonavex focuses on developing innovative ultrasound solutions to provide critical visual and quantitative data, improve patient treatment outcomes, and reduce healthcare costs. Medical ultrasound technology is a crucial imaging diagnostic tool in modern medicine, playing a crucial role in clinical diagnosis and treatment. However, there are still some technical limitations in traditional ultrasound technology, such as limited resolution and imaging quality due to factors such as sound wave frequency and probe size; Real time imaging and high frame rate are ...
- Source: drugdu
- 52
- November 5, 2024
Breaking news, Johnson & Johnson Medical Global Vice President resigns

Not long ago, Larry Jones, Global Vice President and Group Chief Information Officer of Johnson & Johnson MedTech, announced his decision to resign. On the LinkedIn platform, Jones recalled fondly: “Looking back on the 35 glorious years spent at Johnson & Johnson, my heart is filled with deep nostalgia for the extraordinary times we have gone through together.” During his tenure in Johnson & Johnson’s medical device department, Jones was particularly committed to promoting the company’s innovation in oncology, orthopedics, cardiovascular and general surgery, and realizing the innovation of digital surgical connection solutions through advanced technologies such as surgical robots and machine learning platforms. As a senior technology executive, Jones has rich leadership experience. During his decades in office, he has led many major projects in Johnson & Johnson’s pharmaceutical and medical device departments, including the recent three-year, $200 million global digital transformation plan. According to LinkedIn information, Jones is ...
- Source: drugdu
- 58
- November 5, 2024
COVID-19 drugs have become a “dark horse”

The success and failure of COVID-19 are the market’s summary of Pfizer in the past few years. In 2022, COVID-19 vaccines and COVID-19 oral drugs brought Pfizer up to $57 billion in revenue. Relying on the wealth brought by COVID-19 products, Pfizer’s revenue exceeded $100 billion this year, setting a new record for the highest revenue of major pharmaceutical companies. However, as the COVID-19 pandemic dissipated, the global market demand for COVID-19 products fell sharply, and Pfizer was the first to bear the brunt. Faced with the “COVID-19 cliff”, Pfizer had to continue to lower its revenue expectations, and the company’s stock price continued to fall. Last year, it fell by more than 40% throughout the year, and its market value evaporated by nearly $130 billion. In this year’s third quarter report, Pfizer handed in a report card that far exceeded market expectations. Revenue in the third quarter reached $17.7 ...
- Source: drugdu
- 56
- November 5, 2024
After the guidelines were adjusted, GlaxoSmithKline’s RSV vaccine sales plummeted by 74%

Star vaccine products suffered a Waterloo. Last year, the RSV vaccine was amazing; this year, it fell back quickly. Recently, GlaxoSmithKline released its financial report, and its RSV vaccine Arexvy’s sales in the third quarter fell 74% year-on-year, with sales of 188 million pounds, equivalent to 240 million US dollars. So, what caused the decline of Arexvy? According to GlaxoSmithKline, Arexvy suffered a triple blow. The core is that the US Centers for Disease Control and Prevention (CDC) has narrowed the scope of immunization recommendations. Previously, RSV vaccines were recommended for vaccination for people over 60 years old. In June of this year, the US CDC adjusted its recommendations for vaccination populations. After the adjustment, the scope was greatly narrowed, limited to: 1. Adults aged 75 and above. 2. High-risk groups aged 60-74. In addition, the US CDC recommends that it be used only as a single lifetime vaccination. In ...
- Source: drugdu
- 48
- November 5, 2024
Hengrui Medicine’s “2 Category 1 new drugs” approved for clinical trials

Recently, according to the official website of CDE, two Class 1 new drugs of Hengrui Medicine have obtained implicit approval for clinical trials, namely HRS-5632 injection and HRS-6208 capsule. The former is intended to treat lipoprotein disorders, and the latter targets solid tumors. Lipoprotein disorders Lipoprotein disorder refers to the abnormal metabolism of plasma lipoproteins. Studies have shown that it may lead to abnormal transport and distribution of lipids in the blood, thus causing a series of health problems. At present, lipoprotein disorder has been confirmed to be an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), and there is no specific drug to treat it. It is reported that cardiovascular diseases, mainly ASCVD, are the leading cause of death among urban and rural residents in China, accounting for more than 45% of the causes of death. In response to lipoprotein disorder, Hengrui Medicine has deployed a small molecule drug ...
- Source: drugdu
- 79
- November 5, 2024
【EXPERT Q&A】What is the need for a home monitor?

Drugdu.com expert’s response: The necessity of home monitoring devices is mainly reflected in the following aspects: Ⅰ. Enhancing Monitoring Efficiency and Accuracy Home monitoring devices can accurately monitor vital signs, including ECG, blood pressure, blood oxygen levels, body temperature, respiration, and other key indicators. These devices utilize advanced technology to quickly provide reliable data, allowing users to have a clear understanding of their health status. Compared to traditional self-monitoring methods, home monitoring devices are more precise and efficient, aiding in the timely detection of potential health issues. Ⅱ. Meeting the Need for In-home Monitoring With the intensifying trend of population aging and the rising incidence of chronic diseases, an increasing number of elderly individuals require long-term health monitoring. The portability and ease of use of home monitoring devices make in-home monitoring feasible. Elderly individuals can monitor their health at any time in their homes, eliminating the need for frequent visits ...
- Source: drugdu
- 72
- November 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.